In a recent study, using next generation sequencing analysis in a patient-derived ALK-translocated lung cancer cell line after ceritinib treatment, a MAP2K1-K57N activating mutation was found as the primary genetic alteration which was leading to MEK activation. The gene discussed is ALK; the disease is lung cancer.